The 2026 LiBBY trial studied only hospice-eligible people with advanced dementia and major agitation, not parents with early memory change. For adult children, its safety questions belong to end-of-life care, not memory improvement. LiBBY means Life's End Benefits of cannabidiol and tetrahydrocannabinol.
It tested purified oral THC plus CBD against placebo for 12 weeks. Participants averaged 80 years old and received care at home or in residences. That frail, late-stage group faces different risks than a parent living independently with forgetfulness. Adult children need to keep those groups separate when reading headlines.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who qualified for the trial?
- What product was actually tested?
- What changed on benefit and safety?
- What if your parent has early memory loss?
Who qualified for the trial?
The study enrolled 120 hospice-eligible people with advanced dementia and significant agitation, as described by the Alzheimer's Association in its Alzheimer's Association announcement. Enrollment took place across 10 U.S. sites, with visits in homes or residences.
That approach included a population often left out of trials. To qualify, patients needed major neurocognitive disorder with an agitation score of 4 or higher. They also needed hospice enrollment or advanced severity, defined as FAST stage 6D or higher or ADEPT score 12 or higher. The group averaged 80 years old, was 55% female, 84% White and 45% Hispanic or Latino.
- Hospice-eligible with advanced dementia
- Major agitation, not mild restlessness or forgetfulness
- Care at home or in a residence, not a memory clinic
What product was actually tested?
Active treatment was a standardized rapid-acting oil with 2 mg THC plus 100 mg CBD, taken twice daily. It was a purified oral product made for the trial. It was not a dispensary edible, smoked product, or over-the-counter CBD oil.
That distinction matters for safety. Retail cannabis varies in dose, mix, and purity. Results from one fixed oil do not transfer to those varied products.
What changed on benefit and safety?
Treated patients had 6.27 points more improvement on the Cohen-Mansfield Agitation Inventory than placebo at week 2. Benefit persisted through week 12. Clinicians rated 87.2% of treated patients improved at week 12, versus 23.6% on placebo, mainly for restlessness, aggression and distress.
Safety needs careful reading in this frail group. NeurologyLive reported in its NeurologyLive report similar overall adverse events, but more serious events on THC plus CBD, 23.3% versus 11.9%. Serious infections were 11.7% versus 1.7%, and deaths were 13.1% versus 5.1%. Investigators judged the deaths unrelated to drug, but adult children should weigh that pattern with a hospice and palliative team.
What if your parent has early memory loss?
Adults with early forgetfulness, mild cognitive impairment, or earlier-stage dementia were not studied. The Educated Patient noted in its Educated Patient explainer that adult children should not extend end-of-life agitation results to memory improvement. A calmer final weeks does not mean sharper memory earlier.
Do not start THC, CBD, or a combined product for memory on the basis of LiBBY. Ask the clinician about FDA-approved options, drug interactions, fall risk, sedation, and goals of care. Bring a full medication list, sleep and behavior notes, and advance-care wishes to that visit.
You Might Also Like
- LiBBY Trial Findings for Late-Stage Dementia Agitation in 2026: Who Was Studied and Who Was Not for Adult Children
- AAIC 2026 p-tau217 Alzheimer’s Risk Prediction Research: Who Was Studied and Who Was Not for Adult Children
- p-tau217 Findings a Decade Before Alzheimer’s Symptoms in 2026: Who Was Studied and Who Was Not for Adult Children
